Table 1 Relationship between neutrophil-to-lymphocyte ratio and clinicopathological characteristics in patients treated with T-DM1.
n | NLR <2.56a | NLR ≥2.56a | p-value | |
|---|---|---|---|---|
Age (year) | ||||
Median (Range) | 53 | 60.0 (39–79) | 58.4 (43–85) | 0.62 |
Menopausal status b | ||||
Pre- | 4 | 1 (25.0%) | 3 (75.0%) | 0.61 |
Post- | 44 | 22 (50.0%) | 22 (50.0%) | |
ECOG PS c | ||||
0 | 27 | 15 (55.6%) | 12 (44.4%) | 0.41 |
1 and 2 | 26 | 11 (42.3%) | 15 (57.7%) | |
Disease-free interval | ||||
<36 months | 10 | 7 (70.0%) | 3 (30.0%) | 0.76 |
≥36 months | 11 | 7 (63.6%) | 4 (35.4%) | |
Disease control during 1 st line treatment d | ||||
< 12 months | 33 | 15 (45.5%) | 18 (54.5%) | 0.53 |
≥ 12 months | 14 | 8 (57.1%) | 6 (42.9%) | |
Estrogen receptor status | ||||
Positive | 30 | 13 (43.3%) | 17 (56.7%) | 0.41 |
Negative | 23 | 13 (56.5%) | 10 (43.5%) | |
Progesterone receptor status | ||||
Positive | 22 | 7 (31.8%) | 15 (68.2%) | 0.05 |
Negative | 31 | 19 (61.3%) | 12 (38.7%) | |
HER2 IHC status | ||||
2+ with FISH+e | 12 | 5 (41.7%) | 7 (58.3%) | 0.74 |
3+ | 41 | 21 (51.2%) | 20 (48.8%) | |
Primary advanced or recurrence | ||||
Primary advanced | 32 | 12 (37.5%) | 20 (62.5%) | 0.05 |
Recurrence | 21 | 14 (66.7%) | 7 (33.3%) | |
Number of metastatic sites | ||||
1 and 2 | 27 | 15 (56.5%) | 12 (43.5%) | 0.41 |
3 and more | 26 | 11 (43.2%) | 15 (56.8%) | |
Metastatic sites | ||||
Non-visceral | 16 | 8 (50.0%) | 8 (50.0%) | 0.99 |
Visceral | 37 | 18 (48.6%) | 19 (51.4%) | |
Brain metastasis | ||||
No | 41 | 20 (48.8%) | 21 (51.2%) | 0.94 |
Yes | 12 | 6 (50.0%) | 6 (50.0%) | |
Prior endocrine therapy | ||||
Yes | 17 | 7 (41.2%) | 10 (58.8%) | 0.56 |
No | 36 | 19 (52.8%) | 17 (47.2%) | |
Number of prior chemotherapy | ||||
0 and 1 | 26 | 14 (53.8%) | 12 (46.2%) | 0.79 |
2 and 3 | 18 | 8 (44.4%) | 10 (55.6%) | |
4 and more | 9 | 4 (44.4%) | 5 (55.6%) | |
Prior anthracycline | ||||
Yes | 8 | 3 (37.5%) | 5 (62.5%) | 0.70 |
No | 45 | 23 (51.1%) | 22 (48.9%) | |
Prior taxane | ||||
Yes | 41 | 20 (48.8%) | 21 (51.2%) | 0.99 |
No | 12 | 6 (50.0%) | 6 (50.0%) | |
Prior trastuzumab | ||||
Yes | 49 | 22 (44.9%) | 27 (55.1%) | 0.05 |
No | 4 | 4 (100%) | 0 (0%) | |
Prior pertuzumab | ||||
Yes | 32 | 17 (53.1%) | 15 (46.9%) | 0.58 |
No | 21 | 9 (42.9%) | 12 (57.1%) | |
Prior lapatinib | ||||
Yes | 39 | 18 (46.2%) | 21 (53.8%) | 0.54 |
No | 14 | 8 (57.1%) | 6 (42.9%) | |
Reason of treatment discontinuation f | ||||
Disease progression | 27 | 7 (25.9%) | 20 (74.1%) | 0.44 |
Adverse events | 4 | 2 (50.0%) | 2 (50.0%) | |
Others | 4 | 2 (50.0%) | 2 (50.0%) | |
